LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Fondazione IRCCS Istituto Nazionale dei Tumori
Milán, ItaliaPublicaciones en colaboración con investigadores/as de Fondazione IRCCS Istituto Nazionale dei Tumori (18)
2024
-
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 192-204
-
Durvalumab _ Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
Clinical Cancer Research, Vol. 30, Núm. 4, pp. 824-835
2022
-
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1415-1427
-
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
ESMO Open, Vol. 7, Núm. 2
-
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 12, pp. 1301-1311
-
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
JTO Clinical and Research Reports, Vol. 3, Núm. 6
2021
-
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 1, pp. 51-65
-
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
Journal of Thoracic Oncology, Vol. 16, Núm. 5, pp. 860-867
-
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407
Journal of Thoracic Oncology
-
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer
Future Oncology, Vol. 17, Núm. 10, pp. 1165-1184
2020
-
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy
Journal of Thoracic Oncology, Vol. 15, Núm. 5, pp. 709-740
2018
-
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
The Lancet Oncology, Vol. 19, Núm. 4, pp. 521-536
2017
2015
-
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
New England Journal of Medicine, Vol. 373, Núm. 2, pp. 123-135
2012
-
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure
Clinical Cancer Research, Vol. 18, Núm. 11, pp. 3170-3179
2011
2008
-
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II
European Urology, Vol. 53, Núm. 3, pp. 497-513
-
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
European Urology, Vol. 53, Núm. 3, pp. 478-496